Form 4: Elevation Oncology CEO Joseph J. Ferra Jr. Reports Changes in Beneficial Ownership

CEO Joseph J. Ferra Jr. of Elevation Oncology, Inc. reports transactions involving common stock and restricted stock units.

Summary

• On March 16, 2025, Joseph J. Ferra Jr., CEO of Elevation Oncology, Inc., reported changes in his beneficial ownership of the company's securities.
• He acquired 12,562 shares of common stock through the vesting of restricted stock units (RSUs).
• He disposed of 4,628 shares of common stock to cover tax obligations at a price of $0.5328 per share.
• Following these transactions, Ferra directly owns 133,205 shares of common stock and 12,560 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities and ownership positions in the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• The disposal of shares to cover tax obligations could slightly increase the available float.

Key Dates

Keywords

beneficial ownership, Elevation Oncology, Ferra, common stock, restricted stock units, Form 4, securities, transactions